56 citations
,
August 2020 in “American Journal of Clinical Dermatology” This study concluded that the ClinRO and PRO measures, along with their photoguides, offer clear and meaningful assessments for patients with alopecia areata concerning eyebrow, eyelash, and nail appearance, as well as eye irritation.
8 citations
,
February 2018 in “European journal of oncology nursing” This study found that the Hair Mass Index is suitable for quantifying hair loss, but patient self-assessment is the most reliable method for evaluating chemotherapy-induced alopecia in clinical practice.
3 citations
,
February 2025 in “Journal of Dermatological Treatment” This study found a positive association between clinically meaningful scalp hair regrowth and improvements in patient-reported outcomes, such as satisfaction and reduced psychosocial burden.
2 citations
,
March 2025 in “JAMA Dermatology” This review evaluates the quality of alopecia areata-specific patient-reported outcome measures and suggests that more high-quality validation studies are needed to enhance their reliability and validity.
2 citations
,
July 2024 in “Journal of Cosmetic Dermatology” The HAIR-Q is a reliable tool for assessing patient satisfaction with hair loss treatments.
2 citations
,
June 2024 in “Journal of the American Academy of Dermatology” This study evaluated the agreement between clinician and patient assessments of eyebrow and eyelash hair loss severity in adults with severe alopecia areata, using data from two phase 3 studies over 52 weeks.
1 citations
,
January 2025 in “JEADV Clinical Practice” This study reported that the AAPPO tool effectively distinguishes between patients with alopecia areata based on scalp hair loss severity, whereas the EQ‐5D‐5L may underestimate the specific disease burden, particularly in psychological and social aspects.
1 citations
,
July 2021 in “Frontiers in Oncology” This study found that patient-reported outcomes were similar between neoadjuvant endocrine therapy and chemotherapy in premenopausal breast cancer patients, but future perspective was significantly better with endocrine therapy.
May 2011 in “Value in Health” This review assessed patient-reported outcome measures for alopecia treatments but found that none met current FDA guidelines; however, some could potentially be adapted for more comprehensive use.
June 2026 in “British Journal of Dermatology” In this real-world study, 27% of alopecia areata patients treated with ritlecitinib achieved a target SALT score, a result consistent with clinical trial findings, highlighting the value of patient-reported outcomes in understanding treatment impact beyond traditional measures.
March 2026 in “Cancer Diagnosis & Prognosis” In this study, researchers used a patient-reported outcome questionnaire to assess long-term adverse effects in breast cancer patients undergoing chemotherapy, finding persistent symptoms like neuropathy, dysgeusia, insomnia, and nail loss. Peripheral neuropathy was notably prolonged in those receiving anthracycline- and taxane-based regimens compared to docetaxel/cyclophosphamide.
November 2025 in “Journal of Cancer Research and Clinical Oncology” This study from China found that although traditional surgical techniques remain common, endoscopic-assisted surgery is linked with higher patient-reported satisfaction, suggesting its valuable potential for broader application in clinical settings. Factors like reduced bra cup size, surgical method, and implant placement influenced patient satisfaction.
This study found that patient-reported outcomes revealed the persistence of neuropathy, insomnia, and nail changes in breast cancer patients beyond chemotherapy, emphasizing the importance of monitoring long-term adverse events.
January 2025 in “HORMONES” This systematic review reported positive outcomes with gender-affirming hormone therapy in Canada and emphasized the urgent need for standardized outcome measurement tools to enhance evidence-based practices.
May 2024 in “Journal of cosmetic dermatology” This study found that topical finasteride mixed with minoxidil improved hair appearance and self-esteem in men with androgenetic alopecia, but it was not superior to oral finasteride and had lower treatment adherence.
January 2023 in “DIGITAL HEALTH” This study found that users of a German direct-to-consumer teledermatology platform for finasteride reported improvements in hair appearance and self-esteem, though 12% experienced treatment-related adverse events.
4 citations
,
October 2024 in “American Journal of Clinical Dermatology” This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.
September 2024 in “Journal of the American Academy of Dermatology” In this study, patients with severe alopecia areata treated with baricitinib over 152 weeks experienced sustained patient-reported improvements in scalp, eyebrow, and eyelash hair regrowth, with higher responders observed in the 4mg dose group compared to the 2mg group.
May 2025 in “Archives of Dermatological Research” Patient-reported hair improvements align with actual hair density changes, not hair width.
May 2025 in “JEADV Clinical Practice” This study found that using calcipotriene and betamethasone dipropionate cream in a real-world setting significantly improved clinical outcomes and patient quality of life for adults with mild-to-moderate scalp psoriasis, especially among those with higher adherence, demonstrating high treatment satisfaction.
18 citations
,
July 2016 in “British Journal of Dermatology” This review discusses patient-reported outcomes for health-related quality of life in cutaneous lupus erythematosus and reports no new clinical results; the authors note limited existing research and recommend further studies.
2 citations
,
September 2022 in “Annals of Oncology” This study observed that MIRV improved gastrointestinal symptoms and other quality of life measures in patients with platinum-resistant ovarian cancer compared to chemotherapy.
1 citations
,
September 2024 in “Frontiers in Pharmacology” In this real-world study, aumolertinib was found to improve patient-reported outcomes and maintain high disease control and objective response rates similar to those reported in the AENEAS trial for advanced NSCLC patients, supporting its use in first-line treatment.
June 2024 in “Journal of Clinical Oncology” This study observed that dalpiciclib is associated with fewer adverse events like diarrhea and hepatotoxicity compared to other CDK4/6 inhibitors, potentially offering better patient-perceived safety and quality of life.
November 2024 in “SKIN The Journal of Cutaneous Medicine” This study found that generic quality of life questionnaires, like the SF-36 and DLQI, are not sensitive enough to detect differences in health-related quality of life between patients with varying severity of alopecia areata.
82 citations
,
September 2011 in “Quality of Life Research” This review discusses the selection of recall periods for patient-reported outcome measures based on disease attributes, highlighting that inappropriate recall periods can misestimate symptom burden and patient health states; it reports no new findings.
2 citations
,
March 2019 in “PubMed” This report presents the early development of the Lupus Foundation of America's LFA-REAL™ patient-reported instrument, designed to enhance evaluation of lupus disease activity by combining patient and physician assessments.
September 2025 in “Journal of Cutaneous and Aesthetic Surgery” This study found that scalp micropigmentation improved esthetic outcomes and patient satisfaction in scarring alopecia, particularly in conditions with less fibrosis like frontal fibrosing alopecia and traction alopecia.
July 2025 in “Journal of Investigative Dermatology” This study found that high-dose UVA-1 therapy appeared to improve both patient-reported outcomes and objective clinical measures in patients with morphea and systemic sclerosis, supporting its potential efficacy for treating scleroderma.
September 2023 in “Journal of the American Academy of Dermatology”